BIO Thomson Reuters Investor Perception Study
Monday, February 9th
12:30 pm - 1:35 pm
West Foyer
The 2009 BIO Thomson Reuters Investor Perception Study is an in-depth assessment of Wall Street’s views of the biotech industry, its current challenges, its relative valuation, and the outlook for the coming year. The study was fueled by a combination of telephone interviews and an online survey of investment professionals. The purpose of the study is to inform and improve communications between biotech executives, shareholders and policymakers. BIO and Thomson Reuters look forward to announcing the results in February at the 11th Annual BIO CEO & Investor Conference.
Moderator
- John Craighead, Ph.D., Director, Investor Relations and Business Development, BIO
Panelists
- Robert Rynd, Director, Corporate Advisory Services, Thomson Reuters
Who's Who
John Craighead, Ph.D.; Dr. Craighead is the Director of Investor Relations and Business Development with the Biotechnology Industry Organization (BIO). Dr. Craighead is responsible for BIO’s partnering programs and science, business, and policy outreach to the investment community. Prior to joining BIO, Dr. Craighead was a Biotechnology Analyst at Lehman Brothers and the Novartis BioVenture Fund. In his research coverage of the biotechnology industry at Lehman Brothers he published over 300 reports evaluating products in therapeutic categories including oncology, immunology and infectious disease. Dr. Craighead is a National Science Foundation Fellowship recipient and received his Ph.D. in cell biology from the Kellogg School of Science and Technology at The Scripps Research Institute. He has authored numerous scientific papers in the field of eukaryotic transcription regulation, holds a B.A. in chemistry and molecular biology from St. Olaf College, and was awarded the Barry M. Goldwater Scholarship as an undergraduate.
Robert Rynd; Robert Rynd is the Director of the Corporate Advisory Services Biotech team at Thomson Reuters. In this role, Mr. Rynd provides C-suite executives and IROs at life sciences companies with insight, analysis and guidance to support their strategic and tactical decisions. He helps companies understand shareholder activity, trading dynamics, qualitative factors impacting valuation, Wall Street's perceptions and how asset managers invest and behave. He joined Thomson Reuters in 2004. Prior to this he worked as Vice President of Investments within the private wealth management groups at UBS and Morgan Stanley, where he focused primarily on the biotechnology, healthcare, and technology sectors. Education: B.BA, Finance, University of Massachusetts.